Teleflex Incorporated
NYSE:TFXMedical - Instruments & Supplies
+$1.04 today
- Market cap
- $6.58B
- Beta
- 0.82
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$22.79
- Dividend yield
- 1.08%
Volume 1.16M
Average 0.80M
TFX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Teleflex IncorporatedNYSE: TFX
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $45.12M rose 17.1% year over year, behind the +23.6% change in trailing-twelve-month research & development. Sequentially, it rose 1.7% from the prior quarter. Over 3 fiscal years it compounded at -2.0% a year.
Context
- Research & development amounted to 7.3% of revenue in FY2025, up 2.0 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +17.1% toward the trailing-twelve-month pace of +23.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 144.78M USD
- Year-over-year change
- -10.4%
- 4-year CAGR
- +2.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 144.78M | -10.4% |
| FY2024 | 2024-12-31 | 161.67M | +4.7% |
| FY2023 | 2023-12-31 | 154.35M | +0.3% |
| FY2022 | 2022-12-31 | 153.82M | +17.6% |
| FY2021 | 2021-12-31 | 130.84M | — |
Research & Development vs competitors
How TFX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.6% is the 4th highest of 11, against a peer median of +9.4%.
- Research & development amounts to 7.5% of revenue for TFX, versus a peer median of 24.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.03B USD | +74.2% | +67.4% | — | |
| LTM Sep 2026 | $739.14M USD | +21.7% | +29.3% | 164.0% | |
| LTM Jun 2026 | $433.31M USD | -14.7% | -11.3% | 43.0% | |
| LTM Sep 2026 | $430.42M USD | +49.7% | +5.9% | 24.5% | |
| LTM Jun 2026 | $404M USD | +12.5% | +6.5% | 7.6% | |
| LTM Sep 2026 | $283.28M USD | +1.6% | -16.9% | 1125.4% | |
| LTM Sep 2026 | $236.22M USD | +65.3% | +8.5% | 26.3% | |
| LTM Jun 2026 | $195.47M USD | +23.6% | -2.0% | 7.5% | |
| LTM Sep 2026 | $96.93M USD | +1.0% | +8.8% | 6.0% | |
| LTM Jun 2026 | $59.23M USD | +6.3% | +11.0% | 13.4% | |
| LTM Jun 2026 | €25.44M EUR | +5.3% | -10.8% | 2.1% | |
| Peer median (excluding TFX) | — | +9.4% | +7.5% | 24.5% | |
Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.81B | 2.79B | 2.97B | 3.05B | 1.99B |
| Cost of Revenue | 1.26B | 1.26B | 1.33B | 1.34B | 871.96M |
| Gross Profit | 1.55B | 1.53B | 1.65B | 1.7B | 1.12B |
| Gross Margin | 55.2% | 54.9% | 55.4% | 55.9% | 56.2% |
| Research & Development | 130.84M | 153.82M | 154.35M | 161.67M | 144.78M |
| Selling, General & Admin | 860.09M | 863.75M | 929.87M | 995.27M | 720.17M |
| Operating Expenses | 921.51M | 1.03B | 1.14B | 1.55B | 864.95M |
| Depreciation & Amortization | 237.36M | 230.59M | 242.12M | 274.6M | 177.74M |
| EBITDA | 853.8M | 730.77M | 761.21M | 433.62M | 302.51M |
| EBITDA Margin | 30.4% | 26.2% | 25.6% | 14.2% | 15.2% |
| Operating Income | 628.1M | 499.73M | 506.31M | 151.01M | 255.8M |
| Operating Margin | 22.4% | 17.9% | 17.0% | 5.0% | 12.8% |
| Interest Income | 1.33M | 912K | 12.78M | 8.01M | 6.4M |
| Interest Expense | 56.97M | 54.26M | 85.08M | 83.54M | 100.22M |
| Other Income / Expenses | (68.63M) | (53.81M) | (72.3M) | (75.54M) | (231.25M) |
| Income Before Tax | 559.47M | 445.92M | 434.01M | 75.48M | 24.55M |
| Pre-Tax Margin | 19.9% | 16.0% | 14.6% | 2.5% | 1.2% |
| Income Tax Expense | 74.35M | 83M | 76.44M | 5.32M | (33.98M) |
| Net Income | 485.37M | 363.14M | 356.33M | 69.68M | (905.64M) |
| Net Margin | 17.3% | 13.0% | 12.0% | 2.3% | -45.4% |
| EPS (Basic) | 10.38 | 7.74 | 7.58 | 1.49 | (20.30) |
| EPS (Diluted) | 10.23 | 7.68 | 7.53 | 1.48 | (20.25) |
| Weighted Avg Shares | 46.77M | 46.9M | 46.98M | 46.84M | 44.62M |
| Weighted Avg Shares (Diluted) | 47.43M | 47.31M | 47.3M | 47.09M | 44.72M |
Teleflex Incorporated
NYSE:TFX
Intrinsic Alpha fair value
Locked
Current Price
$165.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.